Today’s Sponsor
The biggest AI wins come from companies you don't hear about every day. Like the database provider now embedded into all three major cloud platforms with access to 90% of the market, or the chip giant holding 80% of the AI data center market.
Our 10 Best AI Stocks to Own in 2026 reveals these hidden winners plus a plucky challenger with 28% revenue growth forecasts, a multi-cloud operator with analyst targets near $440, and 6 other AI stocks set to explode. Get the complete list while it's still free.
Get the Free ReportBy clicking the link, you agree to join MarketBeat emails and unlock complimentary insights from select partners. Privacy Policy
Friday, April 3, 2026
Image via The Blaze
States Betting Against AI Are Betting Against Growth
Hollywood has spent decades programming Americans to fear artificial intelligence. From Terminator to Black Mirror, the narrative is always the same: robots bad, regulation good.
But while pop culture peddles dystopia, smart states are embracing AI as an economic accelerator. The winners understand that AI isn't coming to steal jobs — it's coming to create trillion-dollar industries.
States that roll out red carpets for AI companies will capture the next wave of American innovation. Those that cave to technophobia will watch capital flow elsewhere.
✍ My Take: Every anti-AI regulation is a "Welcome to Texas" sign for the next Google or Microsoft. Tech stocks will continue rewarding states that choose progress over panic. Follow the capital flows, not the fear-mongering.
Job Market Crushes Expectations — Again
March employment data just demolished Wall Street's forecasts. The job market isn't cooling — it's accelerating.
Strong employment means consumer spending stays robust. It also means the Fed's rate-cutting timeline just got pushed further into the distance.
✍ My Take: This kills the "soft landing" narrative dead. Expect the Fed to hold rates higher for longer, which is bearish for growth stocks but bullish for financials. The economy doesn't need artificial stimulus when it's already running this hot.
Image via Fox News
Biotech's Next Moonshot: ALS Drug Enters Final Trials
The PREVAiLS study just launched — the only recruiting Phase 3 ALS trial currently active. This isn't just another biotech lottery ticket; it's targeting early-stage patients where intervention actually works.
ALS affects 30,000 Americans with virtually no treatment options. Any drug that shows meaningful efficacy will command premium pricing with guaranteed market demand.
✍ My Take: Breakthrough rare disease treatments create instant billion-dollar markets. While most biotech is speculative gambling, addressing diseases with zero competition and desperate patient populations offers actual risk-adjusted returns. Watch for the data readout.
📎 Fox News
The market rewards reality, not rhetoric. Trade accordingly.
— The Morning Bullets Desk
